Dr. Antoine Lyonel Carre, MD

Dr. Carre practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Carre's NPI, 1629263413, was assigned on September 13, 2007. Dr. Carre graduated from UCSF School of Medicine in 2005. Dr. Carre holds California license A100255.

Dr. Carre's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Carre's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Carre to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Carre practices. Vendor and product names are available with a free account.

Surgery is Dr. Carre's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Carre is board certified in plastic surgery by the American Board of Plastic Surgery. Dmand AI has Dr. Carre's licenses on file in 2 states: California and Massachusetts.

Dmand AI lists breast reconstruction, breast surgery, lymphedema and removal of damaged skin or skin graft among the conditions Dr. Carre treats.

CMS data shows 251 Medicare services from Dr. Carre across 7 procedure codes in 2024, for 109 Medicare patients. Medicare paid $59,588 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 109 Medicare patients who saw Dr. Carre in 2024. The largest group is 65 to 74, with 63 patients. 75% of them have cancer, and 70% have high cholesterol. 35% are also on Medicaid. Their average risk score is 1.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Carre's median patient age at 57, with 90% women.

In 2024, Dr. Carre wrote 23 Medicare Part D claims for 13 patients. 96% of them were for generic drugs. They cover 2 drugs, with $1,322 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Carre for performance year 2024, reported as part of a group. Dr. Carre accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Carre as offering telehealth. CMS counts 23 procedures of mastectomy by Dr. Carre, more than 81% of the clinicians it reports for that procedure.

Hernia repair - groin (open): 1 to 10 procedures (CMS shows small counts as a range)

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 12 papers to Dr. Carre, published from 2008 to 2025. The most frequent topics are Cells, Cultured, Osteogenesis and Adipogenesis. Dr. Carre has published most often in PLoS One. Dr. Carre's most frequent co-authors are Michael Thornton Longaker, MBA, MD, Barrett Jon Larson, MD and Benjamin Levi, MD.

CMS Open Payments shows 121 general payments to Dr. Carre from 27 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 45% of the total. Rti Surgical, Inc paid the most, $7,042.

Dmand AI lists 1 award for Dr. Carre, most recently Fellow in 2014.

Dr. Carre graduated from UCSF School of Medicine in 2005.

Dr. Carre is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.